Abbr. Expansion Instances Papers News
NIH National Institutes of Health
The primary endpoint was the proportion of subjects without a disease progression to severity according to COVID-19 guidelines by the National Institutes of Health (NIH) since randomization to 14 days.
11 8 3
BAU/mL binding antibody units
On day 42, Spike IgG geometric mean ELISA titers were 0.8, 211, and 590 Spike binding antibody units (BAU/mL) for placebo, low-dose and high-dose ECV19, respectively (p  0.001 between groups).
3 2 1
IRRID International Registered Report Identifier
Trial Registration NCT04508972; International Registered Report Identifier (IRRID) DERR1-10.2196/41209
6 6 0
NIV non-invasive ventilation
However, its utility among spontaneously breathing patients is still debated.MethodsIn an open-label randomized controlled trial, we enrolled patients hospitalized with mild COVID-19 pneumonia, whose PaO2/FiO2 ratio was 200 mmHg and who did not require mechanical ventilation (MV) or non-invasive ventilation (NIV) at hospital admission.
5 5 0
MG myasthenia gravis
ObjectiveTo study the COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis (MG).
5 5 0
BCG Bacillus Calmette-Guérin
Aim: We previously published results of the BATTLE trial, showing that patients recently infected with SARS-CoV-2 can benefit from receiving Bacillus Calmette-Guérin (BCG) with minimal adverse effects.
3 3 0
NNT number needed to treat
Treatment effectiveness at various time lags since the first positive RT-PCR swab test was measured by rate of events in the experimental arm (EER) and in the control arm (CER), absolute risk increase (ARI) = (EER − CER), and number needed to treat (NNT) = (1/ARI).
3 3 0
PEP post-exposure prophylaxis
ABSTRACTBACKGROUNDThis study has assessed a new Anti-COVID-19 Monoclonal Antibody Nasal Spray (SA58) for post-exposure prophylaxis (PEP) against symptomatic coronavirus disease 2019 (COVID-19).METHODSWe conducted an efficacy study in adults aged 18 years and older within three days of exposure to a SARS-CoV-2 infected individual.
3 3 0
PP per protocol
The eradication rates in intention to treat (ITT) and per protocol (PP) analyses were: group I, 55.56% and 64.66%; and Group II, 64.44% and 74.36% respectively (p = 0.11).
2 2 0
qRT-PCR quantitative reverse transcription-polymerase chain reaction
Saliva was collected every day and viral load was measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
2 2 0